Amerika Birle\u015fik Devletleri\u2019nde Chicago\u2019da 25-30 Nisan tarihleri aras\u0131nda ger\u00e7ekle\u015ftirilen Amerikan Kanser Ara\u015ft\u0131rmalar\u0131 Derne\u011fi (AACR) Y\u0131ll\u0131k Toplant\u0131s\u0131 2025\u2019te, University of Pennsylvania\u2019n\u0131n Abramson Kanser Merkezi (ACC) ve Perelman T\u0131p Fak\u00fcltesi\u2019nden ara\u015ft\u0131rmac\u0131lar, kanser biyolojisi ve tedavi yakla\u015f\u0131mlar\u0131na y\u00f6nelik \u00f6nemli bulgular\u0131n\u0131 payla\u015ft\u0131. Bu sunumlar, kanser metabolizmas\u0131, imm\u00fcnoterapi ve molek\u00fcler onkoloji alanlar\u0131nda \u00e7\u0131\u011f\u0131r a\u00e7an geli\u015fmeleri i\u00e7eriyor. Penn Medicine\u2019in onkolojik bilimlerdeki liderli\u011fini g\u00f6steren bu \u00e7al\u0131\u015fmalar, kanser tedavisinde yeni ufuklar a\u00e7may\u0131 hedefliyor.<\/p>\n
Toplant\u0131n\u0131n dikkat \u00e7eken isimlerinden biri, Cell and Developmental Biology B\u00f6l\u00fcm\u00fc\u2019nden Arthur H. Rubenstein Profes\u00f6r\u00fc Dr. M. Celeste Simon oldu. Dr. Simon\u2019un konu\u015fmas\u0131, karaci\u011fer ve di\u011fer kanserlerde metabolik yollar\u0131n hedeflenmesiyle tedavi olanaklar\u0131n\u0131 irdeleyen \u00f6nemli bir oturumda yer ald\u0131. Kanser h\u00fccre metabolizmas\u0131n\u0131n sadece t\u00fcm\u00f6r olu\u015fumunun bir sonucu de\u011fil, ayn\u0131 zamanda aktif bir s\u00fcr\u00fcc\u00fcs\u00fc ve terap\u00f6tik bir zaafiyeti oldu\u011fu g\u00f6r\u00fc\u015f\u00fcnden hareketle yap\u0131lan \u00e7al\u0131\u015fmalar, t\u00fcm\u00f6rlerin metabolik ba\u011f\u0131ml\u0131l\u0131klar\u0131n\u0131 ortaya koyuyor. Dr. Simon\u2019un ara\u015ft\u0131rmalar\u0131, bu metabolik ba\u011f\u0131ml\u0131l\u0131klar\u0131n sa\u011fl\u0131kl\u0131 dokulara zarar vermeden selektif olarak hedef al\u0131nabilece\u011fini g\u00f6steriyor.<\/p>\n
Dr. Shelley L. Berger ise epigenetik d\u00fczenleme \u00fczerine yapt\u0131\u011f\u0131 \u00e7al\u0131\u015fmalarla dikkat \u00e7eken isimlerden biri. AACR\u2019nin Kad\u0131n Kanser Ara\u015ft\u0131rmalar\u0131 Charlotte Friend Konferans \u00d6d\u00fcl\u00fc sahibi olan Berger, dinamik kromatin yap\u0131lar\u0131n\u0131n kanserde gen ekspresyonunun d\u00fczenlenmesindeki etkilerini vurguluyor. Epigenetik mod\u00fclat\u00f6rlerin hedeflenmesiyle kansere \u00f6zg\u00fc anormal transkripsiyon paternlerinin tersine \u00e7evrilebilece\u011fini ve b\u00f6ylece kanser h\u00fccrelerinde kaybolan h\u00fccresel kontrol mekanizmalar\u0131n\u0131n yeniden kazand\u0131r\u0131labilece\u011fini ortaya koyuyor. Bu yakla\u015f\u0131m, kanser ilerlemesini durdurma ve tedavi etkinli\u011fini art\u0131rma potansiyeline sahip.<\/p>\n
Emerging scientific talents olarak tan\u0131mlanan Penn\u2019li gen\u00e7 ara\u015ft\u0131rmac\u0131lardan Dr. Christina Demetriadou, metabolizma ve epigenetik aras\u0131ndaki ba\u011f\u0131 anlamaya y\u00f6nelik yeni bulgular\u0131n\u0131 payla\u015ft\u0131. Dr. Kathryn E. Wellen laboratuvar\u0131nda ger\u00e7ekle\u015ftirilen \u00e7al\u0131\u015fmalar, dallanm\u0131\u015f zincirli amino asit metabolizmas\u0131n\u0131n pankreas kanser h\u00fccrelerinde histon propiyonilasyonunu tetikledi\u011fini ortaya koydu. Bu yeni epigenetik modifikasyon, besin metabolizmas\u0131 ile kromatin yap\u0131s\u0131n\u0131n do\u011frudan ba\u011flanmas\u0131n\u0131 sa\u011fl\u0131yor ve t\u00fcm\u00f6r h\u00fccre proliferasyonu ile hayatta kalmas\u0131 \u00fczerinde etkili oluyor. \u00d6zellikle tedaviye diren\u00e7li pankreatik duktal adenokarsinomda bu metabolik-epigenetik etkile\u015fimin hedeflenmesi umut vaat ediyor.<\/p>\n
Hedefe y\u00f6nelik tedaviler alan\u0131nda ise lisans\u00fcst\u00fc \u00f6\u011frenci Gianna T. Busch, tedaviye diren\u00e7li melanom h\u00fccrelerinde ikinci basamak inhibit\u00f6rlere verilen heterojen yan\u0131tlar\u0131 inceledi. BRAFV600E mutasyonuna sahip melanomlarda birinci basamak BRAF inhibit\u00f6rlerine diren\u00e7 geli\u015fimi yayg\u0131n olup, hastal\u0131\u011f\u0131n n\u00fcksetmesini \u00f6nlemek i\u00e7in yenilik\u00e7i kombinasyon stratejileri gerekmekte. Busch\u2019un \u00e7al\u0131\u015fmas\u0131, y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc genetik ve fenotipik analizlerle, diren\u00e7 mekanizmalar\u0131n\u0131 a\u015fan etkili ila\u00e7 kombinasyonlar\u0131n\u0131 tan\u0131mlayarak bu agresif cilt kanseriyle m\u00fccadelede yeni se\u00e7enekler sunuyor.<\/p>\n
Bir ba\u015fka \u00e7arp\u0131c\u0131 geli\u015fme ise KRAS hedefli kanser tedavisinde g\u00f6r\u00fcld\u00fc. Margo I. Orlen\u2019in pankreas kanseri modellerinde ger\u00e7ekle\u015ftirdi\u011fi ara\u015ft\u0131rma, uzun zamand\u0131r ila\u00e7 geli\u015ftirilemeyen RAS onkogenlerini hedefleyen \u2018RAS(ON) multi-selektif inhibit\u00f6rlerin\u2019 t\u00fcm\u00f6r b\u00fcy\u00fcmesini bask\u0131lamakla kalmay\u0131p, t\u00fcm\u00f6r mikro\u00e7evresini de ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin infiltrasyonunu art\u0131racak \u015fekilde yeniden programlad\u0131\u011f\u0131n\u0131 g\u00f6sterdi. Bu strateji, T h\u00fccreleri ve di\u011fer ba\u011f\u0131\u015f\u0131kl\u0131k efekt\u00f6rleriyle i\u015fbirli\u011fi yaparak imm\u00fcnoterapinin etkinli\u011fini y\u00fckseltmekte ve KRAS kaynakl\u0131 malignitelerde yeni bir tedavi paradigmas\u0131 vadetmektedir.<\/p>\n
Penn ara\u015ft\u0131rmac\u0131lar\u0131, ayn\u0131 zamanda PROTAC teknolojisinde de \u00f6nemli ilerlemeler kaydederek, onkogenik proteinlerin se\u00e7ici degradasyonunu h\u0131zland\u0131r\u0131yor. Postdoktoral ara\u015ft\u0131rmac\u0131 Sehbanul Islam, VHL ve KEAP1 bazl\u0131 PROTAC\u2019lar\u0131n kombinasyonunun beklenmedik bir sinerji sergiledi\u011fini ve \u2018hook etkisi\u2019ni azaltarak PROTAC etkinli\u011fini art\u0131rd\u0131\u011f\u0131n\u0131 payla\u015ft\u0131. Bu \u00e7al\u0131\u015fma, daha geni\u015f terap\u00f6tik pencereye sahip ve \u00f6zg\u00fcll\u00fc\u011f\u00fc geli\u015fmi\u015f yeni nesil protein bozucu molek\u00fcllerin geli\u015ftirilmesi a\u00e7\u0131s\u0131ndan temel bilim ve klinik uygulamalara \u0131\u015f\u0131k tutuyor.<\/p>\n
Radyasyon onkolojisi alan\u0131nda da Penn\u2019den \u00f6nemli yenilikler ortaya \u00e7\u0131kt\u0131. Premed \u00f6\u011frencisi Elias El Hoyek, ultra y\u00fcksek doz h\u0131zlar\u0131nda uygulanan FLASH proton radyoterapisinin fare modellerinde korneal (g\u00f6z kornea) hasar\u0131n\u0131 belirgin bi\u00e7imde azaltt\u0131\u011f\u0131n\u0131 ve yara iyile\u015fmesini h\u0131zland\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6sterdi. Bu teknoloji, t\u00fcm\u00f6r hedeflemesini maksimize ederken sa\u011fl\u0131kl\u0131 dokular\u0131n zarar g\u00f6rmesini \u00f6nleme hedefinde devrim yaratacak bir yakla\u015f\u0131m olarak dikkat \u00e7ekiyor ve radyoterapide uzun s\u00fcredir devam eden yan etkiler problemine \u00e7\u00f6z\u00fcm vadediyor.<\/p>\n
\u0130mm\u00fcnoterapi ve nanoteknolojiyi birle\u015ftiren Dr. Khuloud Bajbouj, pankreatik duktal adenokarsinomun stromal bile\u015fenlerine y\u00f6nelik fibroblast aktivasyon proteini (FAP) hedefli CAR T h\u00fccrelerinin in situ lipid nanopartik\u00fcllerle lokal verilmesini sa\u011flayan yenilik\u00e7i bir y\u00f6ntem geli\u015ftirdi. Bu lokal teslimat stratejisi, t\u00fcm\u00f6r mikro\u00e7evresindeki imm\u00fcnosupresif bariyerleri a\u015farak etkin imm\u00fcn h\u00fccre aktivasyonu yarat\u0131yor ve agresif pankreas kanserlerinde t\u00fcm\u00f6r ilerlemesini bask\u0131lamada y\u00fcksek potansiyele sahip.<\/p>\n
Genetik alan\u0131ndaki \u00e7al\u0131\u015fmalar da UNC\u2019dan Penn\u2019e \u00f6zg\u00fc \u00f6nemli veriler i\u00e7eriyor. Postdoktoral ara\u015ft\u0131rmac\u0131 Mwangala Akamandisa, gen\u00e7 BRCA1\/2 mutasyon ta\u015f\u0131y\u0131c\u0131s\u0131 meme kanseri hastalar\u0131nda t\u00fcm\u00f6r\u00fcn molek\u00fcler manzaras\u0131 ve tedaviye y\u00f6nelik sonu\u00e7lar\u0131 analiz etti. Bu \u00e7al\u0131\u015fmalar, kal\u0131tsal mutasyonlar\u0131n \u015fekillendirdi\u011fi \u00f6zg\u00fcn genomik profilleri ve tedavi i\u00e7in hassas noktalar\u0131 tan\u0131mlayarak y\u00fcksek riskli hasta gruplar\u0131nda ki\u015fiselle\u015ftirilmi\u015f onkoloji y\u00f6netimine \u0131\u015f\u0131k tutuyor.<\/p>\n
\u00d6zetle, AACR 2025 Y\u0131ll\u0131k Toplant\u0131s\u0131\u2019nda Penn ara\u015ft\u0131rmac\u0131lar\u0131n\u0131n sunumlar\u0131, t\u00fcm\u00f6r biyolojisinin metabolizma, epigenetik, ba\u011f\u0131\u015f\u0131kl\u0131k ve terap\u00f6tik inovasyon perspektifinden \u00e7ok boyutlu incelenmesini yans\u0131t\u0131yor. Penn Medicine\u2019in bu multidisipliner yakla\u015f\u0131m\u0131, temel bilimle klinik uygulamay\u0131 b\u00fct\u00fcnle\u015ftirerek kanser tedavisinde d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bilgi ve yakla\u015f\u0131mlar\u0131n geli\u015ftirilmesine \u00f6nemli katk\u0131lar sa\u011flamakta.<\/p>\n
AACR etkinli\u011fi ayn\u0131 zamanda alandaki \u00f6nde gelen isimleri onurland\u0131rmak i\u00e7in de bir platform sunuyor. Dr. Shelley L. Berger\u2019in Kad\u0131n Kanser Ara\u015ft\u0131rmalar\u0131 Charlotte Friend Konferans \u00d6d\u00fcl\u00fc ile takdir edilmesi, hem epigenetik kanser ara\u015ft\u0131rmalar\u0131na yapt\u0131\u011f\u0131 \u00f6nc\u00fc katk\u0131lara hem de onkolojide kad\u0131n liderli\u011finin te\u015fvik edilmesine vurgu yap\u0131yor. Ayr\u0131ca, d\u00f6rt Penn ara\u015ft\u0131rmac\u0131s\u0131n\u0131n AACR Akademisi\u2019ne se\u00e7ilmesi, kurumun uluslararas\u0131 kanser ara\u015ft\u0131rmalar\u0131 camias\u0131ndaki kal\u0131c\u0131 etkisini ve bilimsel m\u00fckemmeliyetini g\u00f6steriyor.<\/p>\n
Kanserin d\u00fcnya \u00e7ap\u0131nda olu\u015fturdu\u011fu zorluklar devam ederken, Penn t\u0131p ara\u015ft\u0131rmac\u0131lar\u0131n\u0131n yeni bilimsel ke\u015fifleri ve bunlar\u0131n klinik stratejilerle entegrasyonu, daha etkili, ki\u015fiselle\u015ftirilmi\u015f ve daha az toksik tedavi umudunu y\u00fckseltiyor. Temel biyoloji ile klinik uygulaman\u0131n bulu\u015ftu\u011fu bu bilimsel ortam, bir zamanlar \u00e7aresiz g\u00f6r\u00fclen kanser t\u00fcrlerine kar\u015f\u0131 tedavi umutlar\u0131n\u0131 besleyerek k\u00fcr yolunda ilerlemeye i\u015faret ediyor.<\/p>\n
Sonu\u00e7 olarak, AACR Y\u0131ll\u0131k Toplant\u0131s\u0131 2025, kanserin karma\u015f\u0131kl\u0131\u011f\u0131n\u0131 \u00e7\u00f6zmeye adanm\u0131\u015f bilim insanlar\u0131n\u0131, klinisyenleri ve ara\u015ft\u0131rmac\u0131lar\u0131 bir araya getirdi\u011fi bir bilim havuzu i\u015flevi g\u00f6rd\u00fc. University of Pennsylvania\u2019n\u0131n g\u00fc\u00e7l\u00fc kat\u0131l\u0131m\u0131, akademik bulu\u015flar\u0131n klinik ger\u00e7eklere d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesi konusunda kararl\u0131 duru\u015funu teyit ederken, t\u00fcm d\u00fcnya \u00e7ap\u0131nda farkl\u0131 malignitelerle m\u00fccadele eden hastalar i\u00e7in sonu\u00e7lar\u0131n iyile\u015ftirilmesi ad\u0131na umut verici bir tablo \u00e7izdi.<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Anahtar Kelimeler<\/strong>: Amerika Birle\u015fik Devletleri\u2019nde Chicago\u2019da 25-30 Nisan tarihleri aras\u0131nda ger\u00e7ekle\u015ftirilen Amerikan Kanser Ara\u015ft\u0131rmalar\u0131 Derne\u011fi (AACR) Y\u0131ll\u0131k Toplant\u0131s\u0131 2025\u2019te, University of Pennsylvania\u2019n\u0131n Abramson Kanser Merkezi (ACC) ve Perelman T\u0131p Fak\u00fcltesi\u2019nden ara\u015ft\u0131rmac\u0131lar, kanser biyolojisi ve tedavi yakla\u015f\u0131mlar\u0131na y\u00f6nelik \u00f6nemli bulgular\u0131n\u0131 payla\u015ft\u0131. Bu sunumlar, kanser metabolizmas\u0131, imm\u00fcnoterapi ve molek\u00fcler onkoloji alanlar\u0131nda \u00e7\u0131\u011f\u0131r a\u00e7an geli\u015fmeleri i\u00e7eriyor. Penn Medicine\u2019in onkolojik bilimlerdeki…<\/p>\n","protected":false},"author":1,"featured_media":3407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[2072,2070,2069,2071,2068],"tmauthors":[],"class_list":{"0":"post-3406","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-aacr-2025-kanser-tedavi-yenilikleri","9":"tag-epigenetik-duzenleme-kanser-tedavisi","10":"tag-kanser-metabolizmasi-ve-immunoterapi-gelismeleri","11":"tag-pankreas-kanserinde-metabolik-epigenetik-etkilesim","12":"tag-penn-medicine-kanser-arastirmalari"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Penn-Medicine-AACR-20258217te-Cigir-Acti-1745259273.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3406"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3407"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3406"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nKanser metabolizmas\u0131, epigenetik, imm\u00fcnoterapi, molek\u00fcler onkoloji ve tedavi direnci g\u00f6steren pankreas, melanom, karaci\u011fer ve meme kanseri gibi \u00e7e\u015fitli kanser tiplerinde yeni tedavi yakla\u015f\u0131mlar\u0131.<\/p>\n
\nUniversity of Pennsylvania Researchers Unveil Breakthroughs in Cancer Science at AACR Annual Meeting 2025<\/p>\n
\nNisan 2025<\/p>\n
\nAbramson Cancer Center: https:\/\/www.pennmedicine.org\/cancer
\nPerelman School of Medicine: https:\/\/www.med.upenn.edu\/
\nAACR Annual Meeting 2025: https:\/\/www.aacr.org\/meeting\/aacr-annual-meeting-2025\/
\nShelley Berger AACR Award: https:\/\/www.pennmedicine.org\/news\/news-releases\/2025\/april\/shelley-berger-phd-honored-by-aacr-for-cancer-research
\nM. Celeste Simon Profile: https:\/\/cdb.med.upenn.edu\/people\/m-celeste-simon-ph-d\/<\/p>\n
\nKanser ara\u015ft\u0131rmalar\u0131, metabolizma, epigenetik, imm\u00fcnoterapi, KRAS inhibisyonu, PROTAC teknolojisi, radyoterapi yenilikleri, CAR T h\u00fccre tedavisi, pankreas kanseri, melanom, karaci\u011fer kanseri, meme kanseri, AACR 2025<\/p>\n","protected":false},"excerpt":{"rendered":"